Professor Shareen Doak
Personal Chair
Swansea University Medical School
Telephone: (01792) 295388
Room: Academic Office - 404
Fourth Floor
Institute of Life Science 1
Singleton Campus

Shareen Doak is Professor of Genotoxicology and Cancer in Swansea University Medical School. Shareen is the Medical School's Director of the Centre for NanoHealth and she leads the In Vitro Toxicology Group. Shareen is a UK and EUROTOX Registered Toxicologist, an invited Fellow of the Royal Society of Biology (FRSB) and an elected Fellow of the Learned Society of Wales (FLSW).

Shareen sits on the UK Government Committee on Mutagenicity (COM), and is the Nanomaterials Working Group Co-Leader for the International Genetic Toxicology Technical Committee (GTTC). She is also Senior Editor for Mutagenesis.

Shareen Coordinates the €13Million H2020 PATROLS project (www.patrols-h2020.eu) and is Director of the €12Million  Celtic Advanced Life Science Innovation Network (CALIN), an Ireland-Wales INTERREG operation established to build a innovation bridge between Wales and Ireland in life sciences.

Shareen’s research interests focus on the genotoxic profiles of engineered nanomaterials, the mechanisms underlying their DNA damaging potential and subsequent consequences upon human health. Her interests extend to the development of advanced 3D culture models and mechanism-based bioassays for safety assessment to reduce the need for animal testing.  While her prostate cancer research focuses on understanding the molecular basis of progression to invasive, aggressive disease; with an ultimate aim of identifying a prognostic biomarker panel for improved clinical management of patients.

Areas of Expertise

  • Genetic Toxicology
  • Nanotoxicology
  • DNA Damage Mechanisms
  • Biomarkers / Molecular Biology of Prostate Cancer

Publications

  1. & STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells. Scientific Reports 8(1)
  2. & Characterizing Nanoparticles in Biological Matrices: Tipping Points in Agglomeration State and Cellular Delivery In Vitro. ACS Nano 11(12), 11986-12000.
  3. & Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?. Regulatory Toxicology and Pharmacology 91, 257-266.
  4. & Tissue-Engineered Solutions in Plastic and Reconstructive Surgery: Principles and Practice. 4
  5. & Investigation of J-shaped dose-responses induced by exposure to the alkylating agent N -methyl- N -nitrosourea. Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  6. & Choose your cell model wisely: The in vitro nanoneurotoxicity of differentially coated iron oxide nanoparticles for neural cell labeling. Acta Biomaterialia
  7. & Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDerm™). Particle and Fibre Toxicology 13(1)
  8. & Coating of Quantum Dots strongly defines their effect on lysosomal health and autophagy. Acta Biomaterialia
  9. Opinion of the Scientific Committee on consumer safety (SCCS) - Opinion on the use of 2,2′-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (nano) – S79 – In cosmetic products. Regulatory Toxicology and Pharmacology 76, 215-216.
  10. Wills JW, Johnson GE, Doak SH, Soeteman-Hernández LG, Slob W, White PA Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations..

See more...

Teaching

  • PM-304 Biomolecular Research Project

    *

  • PM-M28 Nano(geno)toxicology

    dfsdf

Supervision

  • Aspirin effects on prostate cancer and development and characterization of prostate cancer spheroids for drug evaluation (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Mechanistic evaluation of the impact of superparamagnetic iron oxide nanoparticles conjugated with drugs (SPIONd) on intracellular signalling/homeostatic mechanisms (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • A Mechanistic Investigation of the Relationship between Extramural Vascular Invasion (EMVI) and CpG Island Methylation Phenotype (CIMP) in Rectal Cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Development of a novel in vitro liver 3D model to assess potential (geno)toxicity of nanomaterials (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Development of a passive dosing system for exposure with hydrophobic compounds in in vitro genotoxicity tests «br /»«br /» (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Deducing the impacts and associated mechanisms of engineered nanoparticles upon telomere status in Lung epithelial cells in vitro. (current)

    Student name:
    MSc
    Other supervisor: Dr Martin Clift
  • Studying the mechanistic process associated with nanoparticle genotoxicity; focusing on NP impact on telomere length (current)

    Student name:
    MSc
    Other supervisor: Dr Martin Clift
  • Examining the Interaction between Adipose Derived Stem Cells (ADSC) and MCF-7 breast cancer in the breast microenvironment: a pilot study (current)

    Student name:
    MPhil
    Other supervisor: Prof Iain Whitaker
  • In Vitro Lung Deposition-Models to Assess the Mechanistic Genotoxicity of Characterised Few-Layer Graphene (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Development of a blood based biomarker for early GI tract cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Understanding the human health impacts of graphene-based nanomaterials under occupational exposure scenarios (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • An advanced multi-cellular and dynamic flow model of the human alveolar airway to study the impact of inhaled particulate (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Investigating the human health implications of e-cigarettes: An in vitro mechanistic toxicology approach. (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Characterising The Role Of Tumourigenic Markers In Prostate Cancer Invasion Through 3D Tumour-Bone Stromal Cell Models (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • "Design and Evaluation of an Antibody-Drug Conjugate for the treatment of aggressive Prostate Cancer" (current)

    Student name:
    PhD
    Other supervisor: Prof Steve Conlan
  • Blood based chemotherapy response monitoring (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Patient reported outcome measures for post facial skin cancer reconstruction (current)

    Student name:
    PhD
    Other supervisor: Prof Iain Whitaker
    Other supervisor: Prof Hayley Hutchings
  • Blood-based test for pancreatic cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • 'In vitro assessment of genotoxicity and cell cycle abnormalities to better understand carcinogenic risk' (awarded 2018)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • 'The molecular mechanisms for chemo-preventative effects of aspirin on prostate cancer' (awarded 2017)

    Student name:
    MSc
    Other supervisor: Prof Steve Conlan
  • 'The role of STEAP2 in Prostate Cancer Progression' (awarded 2017)

    Student name:
    PhD
    Other supervisor: Dr Claire Morgan

External Responsibilities

Research Groups

  • In Vitro Toxicology Group

    Our group focuses on the mechanistic basis for DNA damage induction and persistence, as well as its consequences to human health. The approaches taken by this group involve models of human mutagenesis in vitro in human cells, including genetically modified repair deficient cells, to understand basic mechanisms. Recent work has also focused on assessing 3D human liver and skin models for measuring DNA damage, coupled to automated micronucleus capabilities.

  • Nano(geno)toxicology

    Our research interests lie in understanding the mechanistic basis for DNA damage (genotoxicity) induction and persistence, as well as its consequences to human health following exposure to engineered nanomaterials. We focus on determining genotoxic potential as a function of nanomaterial physico-chemical characteristics and on developing advanced in vitro test systems suited to the assessment of these novel substances.

  • Prostate Cancer

    Our prostate cancer research activity focuses on the identification and validation of molecular biomarkers for the prediction of prostate cancer outcome and evaluating their use as drug targets. The ultimate aim is to achieve patient stratification according to risk for developing metastatic disease with such biomarkers, in order to improve the clinical management of patients.

Administrative Responsibilities

  • Director of Center for NanoHealth (CNH)

    2015 - Present

  • Member - College of Medicine Research Committee

    2012 - Present